Minustosan (Dextromethorphan Hydrobromide)

Dextromethorphan, the active ingredient in Minustosan, is an antitussive presented as an oral formulation for oral use. It suppresses cough associated with dry throat and upper respiratory tract infections in adults and children when appropriate. GNH USA supplies Minustosan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Minustosan, an antitussive, acts on the central cough pathway to reduce unwanted coughing. - Cough: reduces frequency and intensity of dry, non‑productive cough. - Upper respiratory tract infection cough: alleviates cough caused by common colds and viral URTIs. - Irritative throat cough: eases cough triggered by throat irritation from allergens or pollutants.

Common Side Effects: - Nausea: mild stomach upset that usually resolves on its own. - Dizziness: transient light‑headed sensation, especially after the first dose. - Drowsiness: mild sleepiness that may affect alertness. - Constipation: reduced bowel movements, manageable with diet. - Headache: mild to moderate pain, often short‑lived. - Dry mouth: reduced salivation, relieved by fluid intake.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: agitation, tremor, fever when combined with serotonergic agents. - Hallucinations or psychosis: rare central nervous system effects. - Respiratory depression: severe breathing difficulty, especially in overdose. - Seizures: uncommon but possible in susceptible individuals.

Before using Minustosan, consider the following precautions: - Assess underlying cause: ensure cough is non‑productive and not due to a serious condition. - Review medications: avoid concurrent use with serotonergic drugs or MAO inhibitors. - Pregnancy and lactation: consult a healthcare professional; category B1 indicates low risk but caution is advised. - Pediatric use: follow age‑specific recommendations and avoid exceeding recommended amounts. - Driving and machinery: be aware of possible drowsiness that may impair performance. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Dextromethorphan may interact with several drug classes. Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs): increased serotonin levels. - Serotonin‑norepinephrine reuptake inhibitors (SNRIs): potential serotonin toxicity. - Tramadol: additive serotonergic effects. - Linezolid: MAO‑inhibiting properties.

Moderate Interactions (Monitor Closely):\n- Alcohol: enhances central nervous system depression. - CNS depressants (e.g., antihistamines, benzodiazepines): may increase drowsiness. - Anticholinergic agents: can worsen dry mouth. - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): may raise dextromethorphan plasma levels. - Opioid cough suppressants (e.g., codeine): combined effect on cough control should be evaluated.